AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02167958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Pre-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.~Post-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.
Study NCT02167958 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 200 cGy will be administered in a single fraction on Day -1 via linear accelerator.
Study NCT02167958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell infusion
Description: Donors who consent to PBSC donation will receive 5 daily doses of G-CSF, 10 μg/kg/day by subcutaneous injection commencing on day -5. PBSC's will be collected in the afternoon of day -1, stored at 4C overnight, and infused as soon as possible on day 0. If the collection on day -1 contains less than 5.0 X 106 CD34+ cells per kg recipient weight, a second collection will be performed the following morning and infused on day 0. Quantitation of CD34 and CD3 cells will be performed by the Cellular Therapy Lab. For all patients, the target number of CD34 cells to be infused should be 5-6 X 106 cells per kg recipient weight. PBSC in excess of 6.0 x 106 CD34 cells/kg recipient weight may be cryopreserved.
Study NCT02167958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be given at a dose of .03 mg/kg IV over 24 hours. Tacrolimus will be changed to a PO dosing schedule once a therapeutic level is achieved and the patient is tolerating PO. Whole bloodblood levels of tacrolimus will be measured around Day 7 and then should be checked at least weekly thereafter and the dose adjusted accordingly to maintain a level of 5-10 ng/mL. Tacrolimus will be discontinued after the last dose around Day 180, or may be continued if active GVHD is present. Cyclosporine (target concentration 200-400 ng/ml) may be substituted for tacrolimus if the patient is intolerant of tacrolimus.
Study NCT02167958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate
Description: Either the sodium salt of mycophenolate or mycophenolate mofetil (MMF) may be used as prophylaxis of GvHD and will be dosed by actual bodyweight. Only MMF is available as IV formulation. Sodium mycophenolate will be given at a dose of 10mg/kg PO TID rounded to the nearest number of 180mg tablets. MMF will be given at a dose of 15 mg/kg PO TID. The maximum total daily dose should not exceed 2160 mg (sodium salt) or 3 grams (mofetil). Mycophenolate prophylaxis will be discontinued after the last dose on Day 35, or may be continued if active GVHD is present.
Study NCT02167958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is > 1,000/mm3 for three consecutive days.
Study NCT04422236 — intervention group
Intervention type: DEVICE
Intervention: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Description: Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creation of anastomoses during laparoscopic bariatric surgery, manufactured by Ezisurg Medical.
Study NCT02948504 — intervention group
Intervention type: PROCEDURE
Intervention: Coiling or Clipping
Description: All patients are treated under general anesthesia and systemic heparinization. A bolus of 50-75 IU/kg of heparin is given after femoral sheath placement, and intermittent boluses of 1250 IU per hour are given during the procedure. Activated clotting time is maintained at 2-3 times baseline level. Balloon-assisted coiling or stent-assisted coiling are considered in aneurysms with an unfavorable morphology (aneurysm neck≥ 4.0 mm or dome/neck ≤2.0). All anterior circulation aneurysms are clipped through a standard pterional or frontal temporal approach. The posterior circulation aneurysms are treated using far lateral approach depending on the aneurysm location.
Study NCT05505149 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
Study NCT02112461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCP-Hospice Alert
Description: The intervention in Project 1 SCP utilizes a multi-faceted system. The SCP-Hospice symptom management model will include several features: 1) a computer-based telecommunication system to monitor symptoms as perceived and reported by the family caregiver; 2) tailored care management messages that SCP provides directly to the caregivers to promote care management based on the individualized patient symptom profile and caregiver distress; and 3) an automated alerting function that notifies the hospice nurse of unrelieved symptoms that have exceeded a pre-set threshold.
Study NCT00070200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00070200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT00070200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00070200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00070200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00070200 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01941082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6867461
Description: Single or multiple ascending dose by intravitreal injection
Study NCT04238858 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: blood is drawn from the patient's antecubital vein and inserted into four 3.0 ml vacutainer tubes that contain trisodium citrate. These four tubes were placed in a centrifuge machine, and centrifugation was carried out at 2500 rpm (580×g) for 8 min within a 30-min blood collection period. As a result of centrifugation, the plasma was separated in the vacutainer tubes from the remaining blood components. Three different layers formed in the tubes: red blood cells at the bottom, aPRP in the middle layer, and aPPP in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe, and it was immediately injected into the subtenon space of each eye.
Study NCT02673528 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy
Study NCT03669107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gum
Description: no gum
Study NCT01995786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goal Directed Fluid Therapy FloTrac/Vigileo
Study NCT02552823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group1
Study NCT02552823 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group1
Study NCT02552823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group2
Study NCT02552823 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group2
Study NCT02339376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive transcranial magnetic stimulation
Study NCT02339376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation
Study NCT02339376 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Study NCT01886352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Injection of Levobupivacaine in portal sites.
Description: All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
Study NCT01886352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Injection of Levobupivacaine in portal sites.
Description: All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
Study NCT02640092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: Participants will receive \[18F\]GTP1 as per the schedule specified in the arm description.
Study NCT03454178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: WatchBP Office (BP measurement machine)
Description: BP measurement: The nurse or assistant will leave the room after confirmed validity and the WatchBP will automatically measure BP for the participant at 1-minute intervals for 3 more readings; previous research showed that accurate BP readings could be obtained using 1-minute intervals. This is also the measuring method suggested by the manufacturer. The machine will automatically calculate the mean BP using the 3 readings. The mean BP value will be used for analysis. The diagnostic cutoff for diagnosing HT will be ≥135/85 for AOBP
Study NCT03956121 — intervention group
Intervention type: OTHER
Intervention: injection of magnesium sulfate
Description: The intervention consists to perform a study of the usual fetal heart rate with, in addition, comparison analysis of the short-term variability before and after injection of magnesium sulfate in the exposed group. Two successive short-term variability analyzes will be performed in fetuses of the control group.
Study NCT03899441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Two short animated videos - one that reviews minimally-invasive surgery and sentinel lymph node mapping and biopsy for endometrial cancer treatment. This video as reviews possible complications. The second video reviews peri-operative instructions.
Study NCT02387515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive rehabilitation program
Description: Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology. The technological system consists out of motion tracking sensors that register the movements and position of the lumbar spine.
Study NCT00569530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infasurf (ONY Inc.)
Description: Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.
Study NCT00569530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
Study NCT02507544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-818 capsules
Study NCT01226771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin loading dose given
Description: PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
Study NCT01226771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Priming dose of ribavirin given
Description: Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
Study NCT01226771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group C (Standard-of-Care)
Description: PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
Study NCT02844400 — intervention group
Intervention type: DEVICE
Intervention: Biometric Devices
Description: Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.
Study NCT02844400 — intervention group
Intervention type: OTHER
Intervention: Physical Performance Testing
Description: Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.
Study NCT03335449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protective ventilation group
Description: Application of a protective ventilation strategy in order to improve gas exchange and respiratory mechanics during Robotic surgery in deep Trendelenburg position.
Study NCT04238858 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Platelet rich plasma
Description: blood is drawn from the patient's antecubital vein and inserted into four 3.0 ml vacutainer tubes that contain trisodium citrate. These four tubes were placed in a centrifuge machine, and centrifugation was carried out at 2500 rpm (580×g) for 8 min within a 30-min blood collection period. As a result of centrifugation, the plasma was separated in the vacutainer tubes from the remaining blood components. Three different layers formed in the tubes: red blood cells at the bottom, aPRP in the middle layer, and aPPP in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe, and it was immediately injected into the subtenon space of each eye.
Study NCT00324350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents
Description: type 2 diabetes treatments, per standard of care
Study NCT00309049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of IV oral and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
Study NCT00309049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral IV and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
Study NCT00309049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral oral and IV dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
Study NCT03584724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norflo Oro
Description: Norflo Oro is highly bioavailable curcumin complexed into phytosomes
Study NCT03584724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Norflo Oro
Description: Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
Study NCT00664131 — intervention group
Intervention type: OTHER
Intervention: Neurological Examination/Questionnaires
Description: See Detailed Description section for description of treatment plan.
Study NCT01478165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Total intravenous anesthesia
Description: Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
Study NCT01478165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total intravenous anesthesia plus palonosetron
Description: Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
Study NCT03914911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Biopsy Device
Description: The radiologist will perform a routine ultrasonic guided biopsy procedure using the smart biopsy system, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
Study NCT03466242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine
Study NCT03466242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Evaluate sedative and analgesic effects of Intravenous Ketamine
Study NCT00895947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-alpha
Description: a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks
Study NCT00895947 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo lozenges for oral dissolution taken once daily for 16 weeks
Study NCT03084367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: iFR pullback
Description: iFR pullback assessment post angiographically successful PCI
Study NCT02119819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2944876
Description: Administered SC
Study NCT02119819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide extended-release
Description: Administered SC
Study NCT02119819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02647905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System
Description: Accuracy and safety assessment of a continuous glucose monitoring device
Study NCT02119819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral
Study NCT02119819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Oral
Study NCT03507023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metabolaid®
Description: 500 mg per day, in fasting conditions.
Study NCT03507023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg per day, in fasting conditions.
Study NCT01762475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Study NCT01762475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Study NCT01190553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Initiation: IV amantadine 200mg/500ml \* 1/d for 3 days Maintenance: IV amantadine 200mg/500ml once per 6 weeks for 6 months
Study NCT04021849 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Face-to-face Class
Description: The principal investigator will dictate a course about Sexual Harassment, Prevention and Sanction Policies of Cayetano Heredia Peruvian University using PowerPoint Presentation
Study NCT04021849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asynchronous Virtual Class
Description: Every student will have the access to a platform with an Asynchronous Virtual Class that will use the same PowerPoint Presentation of the intervention with an audio recorded by the principal investigator
Study NCT01315132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matched Sibling Allogeneic Transplantation
Description: Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
Study NCT01714232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour® PLUS BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT01714232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch® SelectSimple™ BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT01714232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek® Performa BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT01714232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek® Active BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).